Role of ticlopidine for prevention of stroke.

Abstract

BACKGROUND:

Ticlopidine, an antiplatelet agent with a unique mechanism of action, is now available for clinical use in the United States and Canada.

SUMMARY OF COMMENT:

Recently two large randomized trials demonstrated that ticlopidine can reduce the risk of subsequent stroke in patients presenting with a transient ischemic attack or stroke. One study found that ticlopidine was more effective than aspirin for stroke prevention; however, it was less well tolerated than aspirin and was associated with severe but reversible neutropenia in almost 1% of patients.

CONCLUSIONS:

Ticlopidine is effective for both primary and secondary stroke prevention. It has a favorable risk/benefit ratio and is a particularly attractive option for patients who are unable to take aspirin.

• Authors: G W Albers
• Journal: Stroke (Stroke) Vol. 23 Issue 6 Pg. 912-6 (Jun 1992) ISSN: 0039-2499 [Print] United States
• PMID: 1595115 (Publication Type: Journal Article, Review)

Chemical References

• Drug Combinations
• Ticlopidine

Topics

• Cerebrovascular Disorders (prevention & control)
• Drug Combinations
• Humans
• Risk Factors
• Ticlopidine (adverse effects, pharmacology, therapeutic use)
• Vascular Diseases (drug therapy)